GlassScriptPhysician profile
Janna Adler
NPI 1023452034
$8,635.83
in general payments reported to CMS, 2019-2025
29 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,049 · 2023: $2,060 · 2024: $2,646 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,385 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,384.52 |
| Education | $201.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,215.04 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $1,213.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $1,033.52 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $632.90 | 2022-2025 | Entyvio |
| Celgene Corporation | $451.16 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $348.10 | 2022-2025 | Omvoh, Zepbound |
| Abbvie INC. | $336.26 | 2023-2025 | Rinvoq, Skyrizi |
| Intercept Pharmaceuticals, INC. | $322.14 | 2022-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $318.02 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $273.03 | 2023-2025 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.78 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $219.30 | 2022-2024 | Linzess |
| Qol Medical, LLC | $219.02 | 2023-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $218.55 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $218.05 | 2023-2025 | Ibsrela |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $196.02 | 2024-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $189.73 | 2022-2024 | Dificid |
| Intra-Sana Laboratories | $150.00 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Amgen INC. | $124.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $119.32 | 2024 | |
| Pfizer INC. | $115.22 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $99.64 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $63.70 | 2025 | Iqirvo |
| Exact Sciences Corporation | $49.29 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Genzyme Corporation | $44.89 | 2022 | |
| Braintree Laboratories, INC. | $44.64 | 2023-2025 | Suflave |
| Celltrion USA INC. | $37.96 | 2024 | Zymfentra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janna Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.